311
312
313
314
315
316
317
318
319
320
321
322
323
1.
2.
3.
4.
Bobadilla M, Pariente A, Oca AI, Peláez R, Pérez-Sala Á, Larráyoz IM (2022) Biomarkers as
Predictive Factors of Anti-VEGF Response. Biomedicines 10 DOI 10.3390/biomedicines10051003
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J,
Weichselberger A, Holz FG (2020) HAWK and HARRIER: Phase 3, Multicenter, Randomized,
Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology 127: 72-84 DOI 10.1016/j.ophtha.2019.04.017
Jain A, Chea S, Matsumiya W, Halim MS, Yaşar Ç, Kuang G, Sepah YJ, Khanani AM, Do DV,
Nguyen QD (2020) Severe vision loss secondary to retinal arteriolar occlusions after multiple
intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep 18: 100687 DOI
10.1016/j.ajoc.2020.100687
Haug SJ, Hien DL, Uludag G, Ngoc TTT, Lajevardi S, Halim MS, Sepah YJ, Do DV, Khanani AM
(2020) Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am
J Ophthalmol Case Rep 18: 100680 DOI 10.1016/j.ajoc.2020.100680
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal
RR, Oellers PR, Leveque TK, Rutledge BK, Chittum M, Bacci T, Enriquez AB, Sund NJ, Subong ENP,
Albini TA (2020) Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of
Brolucizumab. Ophthalmology 127: 1345-1359 DOI 10.1016/j.ophtha.2020.04.017
Khanani AM, Zarbin MA, Barakat MR, Albini TA, Kaiser PK, B G, Agashivala N, Yu JS, Wykoff CC,
MacCumber MW (2022) Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular
Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol
140: 20-28 DOI 10.1001/jamaophthalmol.2021.4585
Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, Chin AT, Boyer D, Dayani P,
Arepalli S, Kaiser P (2021) Brolucizumab-early real-world experience: BREW study. Eye (Lond) 35:
1045-1047 DOI 10.1038/s41433-020-1111-x
Bilgic A, Kodjikian L, March de Ribot F, Vasavada V, Gonzalez-Cortes JH, Abukashabah A,
Sudhalkar A, Mathis T (2021) Real-World Experience with Brolucizumab in Wet Age-Related
Macular Degeneration: The REBA Study. J Clin Med 10 DOI 10.3390/jcm10132758
Khoramnia R, Figueroa MS, Hattenbach LO, Pavesio CE, Anderesi M, Schmouder R, Chen Y, de
Smet MD (2022) Manifestations of intraocular inflammation over time in patients on
brolucizumab for neovascular AMD. Graefes Arch Clin Exp Ophthalmol 260: 1843-1856 DOI
10.1007/s00417-021-05518-0
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for
reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140: 509516 DOI 10.1016/j.ajo.2005.03.057
Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA (2010) The multicenter uveitis steroid
treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 149: 550561.e510 DOI 10.1016/j.ajo.2009.11.019
Agrawal RV, Murthy S, Sangwan V, Biswas J (2010) Current approach in diagnosis and
management of anterior uveitis. Indian J Ophthalmol 58: 11-19 DOI 10.4103/0301-4738.58468
Singer M, Albini TA, Seres A, Baumal CR, Parikh S, Gale R, Kaiser PK, Lobach I, Feltgen N, Joshi
MR, Ziemssen F, Bodaghi B (2022) Clinical Characteristics and Outcomes of Eyes with Intraocular
Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER. Ophthalmol Retina
6: 97-108 DOI 10.1016/j.oret.2021.05.003
Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB (2021) Mechanisms of
sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J
Retina Vitreous 7: 37 DOI 10.1186/s40942-021-00307-7
Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein
ML, Martin AA, Hagstrom SA, Martin DF (2014) Risk of geographic atrophy in the comparison of
age-related macular degeneration treatments trials. Ophthalmology 121: 150-161 DOI
10.1016/j.ophtha.2013.08.015
Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F,
Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB,
Jaffe GJ, Liakopoulos S, Monés JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R,
Tufail A, Wolf S, Staurenghi G (2018) Consensus Definition for Atrophy Associated with AgeRelated Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology 125:
537-548 DOI 10.1016/j.ophtha.2017.09.028
Ehlers JP, Patel N, Kaiser PK, Heier JS, Brown DM, Meng X, Reese J, Lunasco L, Le TK, Hu M,
Srivastava SK (2022) The Association of Fluid Volatility With Subretinal Hyperreflective Material
and Ellipsoid Zone Integrity in Neovascular AMD. Invest Ophthalmol Vis Sci 63: 17 DOI
10.1167/iovs.63.6.17
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, SchmidtErfurth U, Holz FG (2021) HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3
Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 128:
89-99 DOI 10.1016/j.ophtha.2020.06.028
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK,
Pruente C, Murray TG, Heier JS (2021) Risk of Inflammation, Retinal Vasculitis, and Retinal
Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Ophthalmology 128: 1050-1059 DOI 10.1016/j.ophtha.2020.11.011
Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, Maruko R, Nakayama M, Yamamoto
A, Koizumi H, Tamashiro T, Terao N, Wakugawa S, Mori R, Onoe H, Tanaka K, Wakatsuki Y,
Itagaki K, Kasai A, Ogasawara M, Sekiryu T, Shintake H, Sugano Y (2021) Brolucizumab-related
intraocular inflammation in Japanese patients with age-related macular degeneration: a shortterm multicenter study. Graefes Arch Clin Exp Ophthalmol 259: 2857-2859 DOI 10.1007/s00417021-05136-w
Chakraborty D, Maiti A, Sheth JU, Boral S, Mondal S, Nandi K, Sinha T, Das A (2021)
Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World
Experience: The BRAILLE Study. Clin Ophthalmol 15: 3787-3795 DOI 10.2147/opth.S328160
Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H (2021) Short-term outcomes of
intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration
with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep
11: 6759 DOI 10.1038/s41598-021-86014-7
Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H (2022) One-year results of treat-andextend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related
macular degeneration with type 1 macular neovascularization. Sci Rep 12: 8195 DOI
10.1038/s41598-022-10578-1
Witkin AJ, Hahn P, Murray TG, Arevalo JF, Blinder KJ, Choudhry N, Emerson GG, Goldberg RA,
Kim SJ, Pearlman J, Schneider EW, Tabandeh H, Wong RW (2021) Brolucizumab-associated
intraocular inflammation in eyes without retinal vasculitis. J Vitreoretin Dis 5: 326-332 DOI
10.1177/2474126420975303
Iyer PG, Peden MC, Suñer IJ, Patel N, Dubovy SR, Albini TA (2020) Brolucizumab-related retinal
vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.
Am J Ophthalmol Case Rep 20: 100989 DOI 10.1016/j.ajoc.2020.100989
Muoio V, Persson PB, Sendeski MM (2014) The neurovascular unit - concept review. Acta Physiol
(Oxf) 210: 790-798 DOI 10.1111/apha.12250
Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ (2015)
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration
Treatments Trials. Ophthalmology 122: 1846-1853.e1845 DOI 10.1016/j.ophtha.2015.05.042
Tenbrock L, Wolf J, Boneva S, Schlecht A, Agostini H, Wieghofer P, Schlunck G, Lange C (2022)
Subretinal fibrosis in neovascular age-related macular degeneration: current concepts,
therapeutic avenues, and future perspectives. Cell Tissue Res 387: 361-375 DOI
10.1007/s00441-021-03514-8
Danis RP, Lavine JA, Domalpally A (2015) Geographic atrophy in patients with advanced dry agerelated macular degeneration: current challenges and future prospects. Clin Ophthalmol 9:
2159-2174 DOI 10.2147/opth.S92359
Detrick B, Hooks JJ (2020) The RPE Cell and the Immune System. In: Klettner AK, Dithmar S (eds)
Retinal Pigment Epithelium in Health and Disease. Springer International Publishing, Cham, pp.
101-114.
418
419
420
421
422
423
424
425
426
427
428
429
430
31.
32.
33.
Sato T, Enoki T, Karasawa Y, Someya H, Taguchi M, Harimoto K, Takayama K, Kanda T, Ito M,
Takeuchi M (2021) Inflammatory Factors of Macular Atrophy in Eyes With Neovascular AgeRelated Macular Degeneration Treated With Aflibercept. Front Immunol 12: 738521 DOI
10.3389/fimmu.2021.738521
Mukai R, Matsumoto H, Akiyama H (2021) Risk factors for emerging intraocular inflammation
after intravitreal brolucizumab injection for age-related macular degeneration. PLoS One 16:
e0259879 DOI 10.1371/journal.pone.0259879
Rezar-Dreindl S, Sacu S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, Krall C, Weigert G,
Schmidt-Erfurth U (2016) The Intraocular Cytokine Profile and Therapeutic Response in
Persistent Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 57: 41444150 DOI 10.1167/iovs.16-19772
431
432
433
Supplemental figures
434
Supplemental Figure 1.Time interval from baseline to the onset of inflammation
435
In this study, 14 (77.8%) eyes developed IOI that presented within 3 months after intravitreal brolucizumab (IVBr)
436
administration. In 11 eyes with IVBr-associated IOI, time interval from initial IVBr administration to the onset of
437
inflammation was 1 month. The onset of anterior or intermediate uveitis was equally distributed from 1 month to 5
438
months after IVBr. In contrast, inflammation developed within 3 months after IVBr in all cases of posterior or pan-
439
uveitis.
440
Supplemental Figure 2
441
Case 1: An 86-year-old man had a BCVA of 1.39 logMAR in the left eye at baseline after 35 injections of other
442
anti-VEGF drugs for neovascular age-related macular degeneration (nAMD). Color fundus photography (CFP) of
443
the left eye showed mild macular atrophy with RPE depigmentation (arrow). (a) OCT image of the left eye showed
444
incomplete RORA with shallow SRF and PED at the macula before the initial intravitreal brolucizumab (IVBr)
445
administration. (b) Four months after the initial IVBr administration when anterior uveitis occurred, his left eye
446
vision was 1.52 logMAR BCVA. CFP showed no haze at 4 months. (c) OCT showed a decreased but still shallow
447
SRF. (d) At that time, his left eye developed anterior uveitis with small KPs (arrowheads) and 1+ cells in the
448
anterior chamber along with 1+ cells in the anterior vitreous. (e) CFP showed no remarkable findings aside from
449
macular atrophy at 5 months. (f) OCT showed no change at 5 months (g) compared with OCT at 4 months (d). At
450
that time, his left eye vision was 1.69 logMAR BCVA.
451
BCVA, best-corrected visual acuity; KP, keratic precipitates; OCT, optical coherence tomography; PED, pigment
452
epithelial detachment; RORA, retinal pigment epithelial and outer retinal atrophy; SRF, sub retinal fluid
453
Supplemental Figure 3
454
Case 2: A 76-year-old man with neovascular age-related macular degeneration (nAMD) in the left eye. His left eye
455
BCVA was 0.22 logMAR at baseline. At that time, color fundus photography (CFP) showed subretinal fluid at the
456
macula (a), and OCT showed subretinal fluid and SHRM (arrow) at the macula. (b) One month later, he developed
457
pan-uveitis in the left eye. His left eye vision decreased to 1.39 logMAR BCVA. CFP showed significant haze (2+).
458
(c) No subretinal fluid and mild residual SHRM were noted on OCT. The image quality was poor because of vitritis.
459
(d) There were diffuse fine KPs (e) and fibrin in the anterior chamber (arrowheads) (f) with anterior inflammation in
460
the left eye. He started betamethasone eye drops 4 times daily and received subtenon’s triamcinolone acetonide 20
461
mg on his left eye. Two months later, his left eye was unremarkable, although his left eye vision was 1.04 logMAR
462
BCVA. At that time, CFP showed no subretinal fluid at the macula (g), and OCT showed no subretinal fluid and no
463
SHRM at the macula. (h)
464
BCVA, best-corrected visual acuity; OCT, optical coherence tomography; KPs, keratic precipitates; SHRM,
465
subretinal hyperreflective material
466
...
論文の公開元へ
